Clearside Biomedical Inc (NASDAQ:CLSD) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Monday.

According to Zacks, “Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia. “

Several other equities analysts also recently weighed in on the company. Wedbush reissued a “buy” rating and set a $28.00 price target on shares of Clearside Biomedical in a research report on Thursday, August 25th. Stifel Nicolaus started coverage on Clearside Biomedical in a research report on Monday, June 27th. They set a “buy” rating and a $13.00 price target for the company. Needham & Company LLC started coverage on Clearside Biomedical in a research report on Tuesday, June 28th. They set a “buy” rating and a $16.00 price target for the company. Finally, Cowen and Company started coverage on Clearside Biomedical in a research report on Monday, June 27th. They set an “outperform” rating for the company. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $16.19.

Shares of Clearside Biomedical (NASDAQ:CLSD) opened at 11.01 on Monday. The stock’s market cap is $226.20 million. Clearside Biomedical has a 12-month low of $5.65 and a 12-month high of $12.00. The company has a 50 day moving average price of $7.52 and a 200 day moving average price of $7.12.

Clearside Biomedical (NASDAQ:CLSD) last released its quarterly earnings data on Thursday, August 11th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.32) by $0.30. Analysts anticipate that Clearside Biomedical will post ($2.10) earnings per share for the current fiscal year.

Several large investors have recently bought and sold shares of CLSD. AWM Investment Company Inc. acquired a new stake in Clearside Biomedical during the second quarter valued at about $350,000. Iguana Healthcare Management LLC acquired a new stake in Clearside Biomedical during the second quarter valued at about $526,000. Marshall Wace LLP acquired a new stake in Clearside Biomedical during the second quarter valued at about $1,122,000. Finally, Perceptive Advisors LLC acquired a new stake in Clearside Biomedical during the second quarter valued at about $4,450,000.

Clearside Biomedical Company Profile

Clearside Biomedical, Inc is a late-stage clinical biopharmaceutical company. The Company is developing drug therapies to treat blinding diseases of the eye. The Company’s product candidates are focused on diseases affecting the retina and choroid, especially diseases associated with macular edema, and are injected into the suprachoroidal space (SCS) adjacent to the choroid, using its SCS Microinjector.

5 Day Chart for NASDAQ:CLSD

Get a free copy of the Zacks research report on Clearside Biomedical (CLSD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Clearside Biomedical Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.